---
layout: default
title: Vincristine
parent: Model Prediction Only (L5)
nav_order: 357
evidence_level: L5
indication_count: 2
monitor_inn: "Vincristine"
predicted_indications: ["vertebral anomalies and variable endocrine and T-cell dysfunction", "retroperitoneal neoplasm"]
last_modified_at: 2026-10-23
description: "Vincristine: predicted new indication Vertebral anomalies and variable endocrine and T-cell dysfunction (evidence level L5). Approved use: Not recorded in the local data"
---

# Vincristine
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **2** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist" markdown="1">

## Pharmacist Assessment Report

</div>

## Vincristine: Vertebral anomalies and variable endocrine and T-cell dysfunction
{: .text-alpha }

## One-Sentence Summary

Vincristine is a cytotoxic anticancer drug. Its known uses include acute lymphoblastic leukemia, Hodgkin and non-Hodgkin lymphoma, mantle cell lymphoma and Langerhans cell histiocytosis. The TxGNN model (deep learning) predicts it may be effective for **vertebral anomalies and variable endocrine and T-cell dysfunction**, a rare congenital syndrome. **No clinical trials and no publications** currently support this prediction, so it rests on a computational score alone.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Vertebral anomalies and variable endocrine and T-cell dysfunction |
| TxGNN Prediction Score | 0.9924 |
| Evidence Level | L5 (model prediction only) |
| Philippines Market Status | Marketed (valid licenses: 1 of 1) |
| Number of Registrations | 1 (valid: 1) |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the data compiled for this report. Vincristine is generally known as a vinca alkaloid that blocks microtubule formation and arrests dividing cells in mitosis. This makes it cytotoxic to rapidly dividing cells, which fits its use in lymphoid cancers.

A mechanistic link to the predicted condition could not be established. The condition is a rare congenital syndrome with vertebral, endocrine and T-cell features. It is not a cancer of rapidly dividing cells, and no plausible pathway connects an antimitotic drug to it. The high score (0.9924) comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological or clinical evidence. The prediction should be treated as a hypothesis only.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Philippines Market Information

| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---------|------|------|-----------|
| PNF-0515 | Vincristine | Not specified | Not specified |

This is a single-ingredient product with valid status. The licence record contains no indication text, so the local approved use cannot be confirmed from the data compiled for this report.

---

## Cytotoxicity

| Item | Content |
|------|------|
| Cytotoxicity Classification | Conventional cytotoxic (vinca alkaloid, antimitotic) |
| Myelosuppression Risk | Low to medium. Neurotoxicity is usually the dose-limiting effect, but blood counts should still be checked |
| Emetogenicity Classification | Low |
| Monitoring Items | CBC with differential, liver function (including bilirubin), neurological examination |
| Handling Protection | Must follow cytotoxic drug handling regulations. Please refer to the package insert warnings and precautions for administration precautions |

---

## Safety Considerations

- **Contraindication relations in the knowledge graph (not label text):** liver failure, cholestasis, hyperbilirubinaemia (including Gilbert syndrome), leukopenia, peripheral neuropathy and other neuromuscular diseases (including Charcot-Marie-Tooth disease), acute urate nephropathy, and fungal and other infectious diseases.
- **Drug Interactions:** the interaction query returned 100 records, and 20 are shown in the data compiled for this report. One is rated **Major**: clarithromycin. Most of the rest are rated Moderate, including aprepitant, dexamethasone, metronidazole, eliglustat, naltrexone, miconazole, rolapitant, rosuvastatin, simvastatin, tinidazole and troglitazone. Levofloxacin is rated Minor.

Please refer to the package insert for warnings and contraindications from the label.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction has a very high model score but no supporting trials or publications, and no plausible mechanism links an antimitotic cytotoxic drug to this congenital syndrome. Vincristine also carries substantial toxicity, so there is no basis to proceed.

**To proceed, the following is needed:**
- A mechanistic rationale, supported by detailed mechanism of action data, linking vincristine to the biology of this syndrome.
- Any preclinical or clinical study that directly addresses this condition.
- The Philippines package insert, covering the approved indication, warnings and contraindications.
- A risk–benefit assessment, since cytotoxic exposure in a non-malignant congenital condition is a major concern.

**Note on a second candidate:** The same analysis also ranked **retroperitoneal neoplasm** (score 0.9923). That prediction has 20 retrieved publications, mostly case reports of vincristine-containing regimens in rhabdomyosarcoma, paraganglioma and similar tumours, and no registered trials. Because "retroperitoneal neoplasm" is an anatomical category rather than a single disease, the evidence is indirect, and it is better treated as a separate research question.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

